Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Enfortumab Vedotin

NCT06891560

Memorial Sloan Kettering · Phase 2 · Recruiting · Enrollment 34

NCT06891560

Catalyst Primary completion. 03.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety

A count stays a count. This page does not turn a count into a percent.